Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.231 | Does influenza activity trigger asthma exacerbations in Hong Kong? A retrospective modelling analysis | Dr. CHONG Ka Chun |
| 2021.742 | Exposure to fine particulate matter and the risk of hospitalization for cardiovascular disease in patients with type 2 diabetes: A retrospective cohort study | Dr. CHONG Ka Chun |
| 2021.045 | Impact of air pollution on hospital admission for respiratory diseases over the past two decades in Hong Kong | Dr. CHONG Ka Chun |
| 2021.096 | Spatial Resources Allocation and Dynamics Planning for Public Healthcare Services | Dr. CHONG Ka Chun |
| 2023.510 | Predictive Modelling for Postoperative Complication Risk Assessment | Dr. CHONG Ka Chun |
| 2021.087 | Is influenza associated with early onset of hospitalization for common chronic diseases in the elderly population? A modelling analysis | Dr. CHONG Ka Chun |
| 2024.367 | Association between SARS-CoV-2 rebound and post-COVID-19 conditions: a retrospective cohort study | Dr. CHONG Ka Chun |
| 2024.344 | Impact of temperature variation on mortality during extreme temperature events in Hong Kong | Dr. CHONG Ka Chun |
| 2015.439 | Pressure ulcer prevention and management: evaluation of a home-based education program for caregivers of elderly: A pilot study |
Ms. CHONG Ka Wing 莊嘉穎 |
| 2023.518 | A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE |
Dr. CHONG Kam Lung 莊金隆 |
| 2022.215 | Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease: A Multicentre, Randomized, Double-masked, Placebo-controlled Clinical Trial |
Dr. CHONG Kam Lung 莊金隆 |
| 2008.019 | Biomarkers in Thyroid Eye Disease (TED) / Graves' Ophthalmopathy (GO) | Dr CHONG Kam lung |
| 2007.467 | Moh's Micrographic Surgery (MMS) in Hong Kong for the Treatment of periocular Basal Cell Carcinoma (BCC) through a Multidisciplinary Approach | Dr Chong Kam-lung Kelvin |
| 2010.594 | Biological changes in Thyroid associated orbitopathy/Graves’ Ophthalmopathy (TAOB): Hong Kong Thyroid Eye Assessment and Management (HK-TEAM) Study | Dr. CHONG Kelvin Kam Lung |
| 2017.433 | Identification of new susceptibility and disease-causing genes in the pathogenesis and prediction of thyroid associated orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2015.298 | Change in retinal, choroidal and nerve fiber layer thickness in thyroid associated orbitopathy |
Prof. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.151 | Registry of oculoplastic and adnexal disorders (ROAD) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2014.530 | Prevalance and progression of open angle glaucoma and ocular hypertension in thyroid-associated orbitopathy (TAO) patients in the Hong Kong Chinese population | Dr. CHONG Kelvin Kam Lung |
| 2017.037 | Ocular Hypertension and Glaucoma in Thyroid Associated Orbitopathy |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.025 | 3D-printed Surgical Instruments and Orbital Models (3SIOM) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.327 | A randomized, double-masked, clinical trial comparing extended vs standard endonasal dacryocystorhinostomy (ExStEND) for primary acquired nasolacrimal duct obstruction |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2016.038 | Mitomycin, Intubation vs No adjuvant In MUcosal-preserving Mechanical endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction (MINIMUM endonasal DCR for PANLDO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2017.570 | IgG4-related ophthalmic disease (IgG4-ROD) in Hong Kong |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2016.325 | Combined Radiotherapy and Intravenous Steroid for Early Progressive Thyroid Eye Disease |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2024.294 | Supporting orthoptic assessment for moderate-to-severe active Thyroid Eye Disease patients with diplopia | Dr. CHONG Kelvin Kam Lung |
| 2019.489 | Multiparametric MRI-based radiological activity score (RAS) in Thyroid Associated Orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.097 | Efficacy and safety of Intense Pulsed Light (IPL) on dry eye associated with Thyroid Associated Orbitopathy (TAO) |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2019.007 | Infrared Pupillometry and Eye-tracking as Next-generation Non-Intrusive Means to Identify Subjects Under Influence of Psychoactive Drug and Vision-related Harms |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.465 | Ocular microenvironment and mucosal microbiota reveal COVID-19 severity, transmissibility and model drug responses |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.478 | Hong Kong IgG4-Related Disease Registry |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2020.349 | Early detection and surveillance of COVID-19 infection by non-invasive ophthalmic evaluations |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2014.129 | Validation of immunophilins FK506-binding proteins (FKBPs) and their autoantibodies in rapid diagnosis of Thyroid associated orbitopathy (TAO) disease progression | Dr. CHONG Kelvin Kam Lung |
| 2014.124 | Novel strategy using peripheral blood mononuclear cells (PBMC) as a rapid diagnosis for Thyroid-Associated Orbitopathy (TAO) | Dr CHONG Kelvin Kam Lung |
| 2014.138 | Using topical CSA to control ocular surface inflammation and improves dry eyes in patients with thyroid eye disease | Prof Chong Kelvin Kam Lung |
| 2014.128 | Standard diagnostic algorithm for dysthyroid optic neuropathy – Systematic application of clinical investigational devices | Dr. CHONG Kelvin Kam Lung |
| 2023.422 | A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Preliminary Efficacy, Immunogenicity, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients with Pulmonary Fibrosis or Thyroid Eye Disease | Prof. CHONG Kelvin Kam Lung |
| 2021.473 | Mapping the Thyroid Associated Orbitopathy (TAO) Genes by Whole Genome Sequencing (WGS) | Dr. CHONG Kelvin Kam Lung |
| 2022.582 | Efficacy and tolerability of 0.2% hyaluronic acid & 2% ectoin topical eye drops, Vitamin A ointment, and lid wipe in post-COVID Meibomian Gland Dysfunction (MGD): a 3-arm randomized clinical trial |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2023.528 | SAfe immunomodulation reserVEd for Mild-to-mOderate, REcent-onset TED (SAVE-MORE-TED) - a multi-center, randomized, double-masked, placebo-controlled trial | Dr. CHONG Kelvin Kam Lung |
| 2023.352 | Ocular surface damage and alteration in microbiome among cocaine and ice users - a prospective observational study for their health enhancement | Dr. CHONG Kelvin Kam Lung |
| 2022.199 | Deep learning and radiomics algorithm of neuroimaging for TED in Hong Kong – A territory-wide study from the HADCL |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2023.191 | Site-specific microbiome in common lacrimal gland disorders | Dr CHONG Kelvin Kam Lung |
| 2021.271 | Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress (VIEW) therapies for meibomian gland dysfunction - a multicentre, randomized, assessor-masked, active-controlled clinical trial |
Dr. CHONG Kelvin Kam Lung 莊金隆 |
| 2023.622 | Projecting the impact of population aging on mortality attributable to extreme heat | Dr. CHONG Marc Ka Chun |
| 2019.440 | Development of objective measure of psychotropic substances abuse using Automatic Retinal Image Analysis (ARIA) |
Dr. CHONG Marc Ka Chun 莊家俊 |
| 2020.263 | Factors associating with participation and adherence of cardiac rehabilitation programme among coronary heart disease patients | Ms. CHONG Mei Sin |
| 2020.621 | Effectiveness of Technology-assisted Interventions in Hybrid Cardiac Rehabilitation (TecHCR) among Coronary Heart Disease Patients | Ms. CHONG Mei Sin |
| 2019.464 | Retrospective study of mitochondrial disorders in Hong Kong |
Dr. CHONG Shuk Ching 莊淑貞 |
| 2019.293 | Metabolomics profiling study for patients with citrin deficiency |
Dr. CHONG Shuk Ching 莊淑貞 |
| 2019.685 | Parental attitudes on newborn genetics screening program in Hong Kong |
Prof. CHONG Shuk Ching 莊淑貞 |
Page 83 of 254.